Page last updated: 2024-12-09

cefpiramide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cefpiramide: antipseudomonal cephalosporin derivative [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

cefpiramide : A third-generation cephalosporin antibiotic with [(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl and (R)-2-{[(4-hydroxy-6-methylpyridin-3-yl)carbonyl]amino}-2-(4-hydroxyphenyl)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton. It has a broad spectrum of antibacterial activity. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID636405
CHEMBL ID1201204
CHEBI ID59213
SCHEMBL ID49253
MeSH IDM0111490

Synonyms (57)

Synonym
cefpiramide (usp/inn)
D03428
70797-11-4
cefpiramide
DB00430
NCGC00167444-01
wy-44635
(6r,7r)-7-{[(2r)-2-{[(4-hydroxy-6-methylpyridin-3-yl)carbonyl]amino}-2-(4-hydroxyphenyl)acetyl]amino}-3-{[(1-methyl-1h-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
7beta-[(2r)-2-{[(4-hydroxy-6-methylpyridin-3-yl)carbonyl]amino}-2-(4-hydroxyphenyl)acetamido]-3-{[(1-methyl-1h-tetrazol-5-yl)sulfanyl]methyl}-3,4-didehydrocepham-4-carboxylic acid
cefpiramidum
cefpiramido
CHEBI:59213 ,
(6r,7r)-7-[[(2r)-2-(4-hydroxyphenyl)-2-[(6-methyl-4-oxo-1h-pyridine-3-carbonyl)amino]acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
cefpiramide acid
wy-44,635
nsc-759869
CHEMBL1201204
dtxsid6046630 ,
dtxcid4026630
tox21_112448
cas-70797-11-4
cefpiramide [usan:usp:inn]
p936ya152n ,
cefpiramido [inn-spanish]
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((((4-hydroxy-6-methyl-3-pyridinyl)carbonyl)amino)(4-hydroxyphenyl)acetyl)amino)-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-, (6r-(6alpha,7beta(r*)))-
cefpiramidum [inn-latin]
wy 44635
nsc 759869
(6r,7r)-7-((r)-2-(4-hydroxy-6-methylnicotinamido)-2-(p-hydroxyphenyl)acetamido)-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
unii-p936ya152n
cefpiramide [mart.]
cefpiramide [usan]
cefpiramide [mi]
cefpiramide [who-dd]
cefpiramide [usp-rs]
cefpiramide [usp impurity]
cefpiramide [inn]
S5186
AKOS025311237
CCG-221235
SCHEMBL49253
(6r,7r)-7-((r)-2-(4-hydroxy-6-methylnicotinamido)-2-(4-hydroxyphenyl)acetamido)-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6r,7r)-7-[(2r)-2-[(4-hydroxy-6-methylpyridin-3-yl)formamido]-2-(4-hydroxyphenyl)acetamido]-3-{[(1-methyl-1h-1,2,3,4-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
mfcd00864893
HMS3715H12
(7r)-7-((r)-2-(4-hydroxy-6-methylnicotinamido)-2-(4-hydroxyphenyl)acetamido)-3-((1-methyl-1h-tetrazol-5-ylthio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6r,7r)-7-((r)-2-(4-hydroxy-6-methylnicotinamido)-2-(4-hydroxyphenyl)acetamido)-3-((1-methyl-1h-tetrazol-5-ylthio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Q4921174
AS-14170
BRD-K92872987-001-02-9
NCGC00167444-04
(7r)-7-[[(2r)-2-(4-hydroxyphenyl)-2-[(6-methyl-4-oxo-1h-pyridine-3-carbonyl)amino]acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
EN300-19766072
gtpl12027
HY-B1354
CS-0013097
cefpiramide acid;cefpiramido;cefpiramidum;wy-44635;sm-1652

Research Excerpts

Overview

Cefpiramide (CPM) is a new cephalosporin with good activity against Pseudomonas. It is mainly excreted in the bile and has a broad spectrum of antibacterial activity.

ExcerptReferenceRelevance
"Cefpiramide (CPM) is a newly developed cephalosporin. "( [Clinical evaluation of cefpiramide in pediatrics].
Aoyama, R; Asuka, N; Chiba, C; Fujita, M; Izumi, Y; Kakizaki, Y; Kudo, M; Ohnishi, A; Tsushima, N; Waga, S, 1983
)
2.02
"Cefpiramide is a new parenteral cephalosporin mainly excreted in the bile. "( Cefpiramide kinetics and plasma protein binding in cholestasis.
Amouretti, M; Bannwarth, B; Demontes-Mainard, F; Kieffer, G; Labat, L; Necciari, J; Vinçon, G, 1994
)
3.17
"Cefpiramide (CPM) is a new cephalosporin with good activity against Pseudomonas. "( [Bactericidal activity of cefpiramide on P. aeruginosa using an in vitro pharmacokinetic simulation model].
Combes, T; Drigues, P; Labrousse, M; Mas, C; Roche, G, 1986
)
2.01
"Cefpiramide is a new Pseudomonas-active cephalosporin with a broad spectrum of antibacterial activity. "( Cefpiramide: comparative in-vitro activity and beta-lactamase stability.
Ayers, LW; Barry, AL; Fuchs, PC; Gavan, TL; Gerlach, EH; Jones, RN; Sommers, HM; Thornsberry, C, 1985
)
3.15

Pharmacokinetics

The mean plasma half-life of cefpiramide in 15 subjects who received a single dose of 500 or 1,000 mg was 4. In ten cholecystectomized patients provided with a T-tube, intravenous injection of 1 g of ceferpiramide resulted during the 2nd hour in a biliary peak concentration of 1161 +/- 392 micrograms/ml. The pharmacokinetic properties of cferpiramide were superior to those of cecotaxime and cefoperazone.

ExcerptReferenceRelevance
" In patients with cirrhosis the plasma elimination half-life was three times longer than that in normal subjects."( Pharmacokinetics and protein binding of cefpiramide in patients with alcoholic cirrhosis.
Amouretti, M; Begaud, B; Demotes-Mainard, F; Dumas, F; Kieffer, G; Necciari, J; Vinçon, G, 1991
)
0.55
" The elimination half-life of the antibiotic was prolonged in CCl4-intoxicated rats and the total body clearance in CCl4-intoxicated rats (153."( Pharmacokinetics of cefpiramide in rats acutely intoxicated with carbon tetrachloride.
Kimura, T; Kurosaki, Y; Li, C; Nakayama, S; Nakayama, T, 1990
)
0.6
" We studied CPM killing kinetics using an in vitro model that simulates the pharmacokinetic profile observed in humans following a single intramuscular injection."( [Bactericidal activity of cefpiramide on P. aeruginosa using an in vitro pharmacokinetic simulation model].
Combes, T; Drigues, P; Labrousse, M; Mas, C; Roche, G, 1986
)
0.57
" In ten cholecystectomized patients provided with a T-tube, intravenous injection of 1 g of cefpiramide resulted during the 2nd hour in a biliary peak concentration of 1161 +/- 392 micrograms/ml."( Experimental and clinical evaluation of the biliary pharmacokinetic profile of cefpiramide, a new cephalosporin with high hepatic elimination.
Arnaud, JP; Blickle, JF; Brogard, JM; Jehl, F; Monteil, H, 1988
)
0.72
"To investigate possible mechanisms for the long-lasting pharmacokinetic properties of cefpiramide, pharmacokinetic and renal clearance studies were carried out using rabbits."( Renal tubular mechanisms for excretion of cefpiramide (SM-1652) in association with its long-lasting pharmacokinetic properties.
Matsui, H; Okuda, T, 1988
)
0.76
" The pharmacokinetic properties of cefpiramide in mice and rats were superior to those of cefotaxime and cefoperazone."( Experimental efficacy and pharmacokinetic properties of cefpiramide, a new cephalosporin.
Chiang, ST; Fu, KP; Gregory, FJ; Hung, PP; McCloud, S; Vince, T, 1985
)
0.79
"Human pharmacokinetic parameters are often predicted prior to clinical study from in vivo preclinical pharmacokinetic data."( Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Jolivette, LJ; Ward, KW, 2005
)
0.33

Compound-Compound Interactions

ExcerptReferenceRelevance
"Cefpiramide and cefoperazone alone and in combination with gentamicin were compared for therapeutic efficacy against pseudomonal infections in normal mice and in mice made neutropenic by administration of cyclophosphamide."( Therapeutic efficacy of cefpiramide and cefoperazone alone and in combination with gentamicin against pseudomonal infections in neutropenic mice.
Fu, KP; Gregory, FJ; Hetzel, N; Hung, PP, 1986
)
2.02

Bioavailability

ExcerptReferenceRelevance
"Cefpiramide (SR 95445) (CPM) is a new cephalosporin with activity against Pseudomonas and a good bioavailability following parenteral administration."( [Beta-lactamase induction in Pseudomonas aeruginosa by cefpiramide and 3 other antipyocyanic cephalosporins].
Combes, T; Drigues, P; Lanau, C; Roche, G; Salhi, A, 1986
)
1.96
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Dose regimen of cefpiramide should be modified in patients with cholestasis. Because the rate of elimination from plasma in patients is slower, the dosage regimen would probably bemodified in cirrhosis.

ExcerptRelevanceReference
" Because the rate of elimination from plasma in patients is slower, the dosage regimen of cefpiramide would probably be modified in cirrhosis."( Pharmacokinetics and protein binding of cefpiramide in patients with alcoholic cirrhosis.
Amouretti, M; Begaud, B; Demotes-Mainard, F; Dumas, F; Kieffer, G; Necciari, J; Vinçon, G, 1991
)
0.77
" The duration and dosage of CPM, selected in the study, were both satisfactory for prevention of infection in open heart surgery."( [Prophylactic use of cefpiramide (CPM) in open heart surgery].
Fukuda, S; Iguro, Y; Koga, M; Morishita, Y; Moriyama, Y; Taira, A; Takenaka, K, 1989
)
0.6
" CPM was administered in 2 or 3 divided doses at a daily dosage ranging from 41."( [Clinical evaluation of cefpiramide in pediatrics].
Haruta, T; Kobayashi, Y; Kuroki, S; Okura, K; Yamakawa, M, 1983
)
0.57
" Accordingly, the dosage regimen of cefpiramide should be modified in patients with cholestasis."( Cefpiramide kinetics and plasma protein binding in cholestasis.
Amouretti, M; Bannwarth, B; Demontes-Mainard, F; Kieffer, G; Labat, L; Necciari, J; Vinçon, G, 1994
)
2.01
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
antibacterial drugA drug used to treat or prevent bacterial infections.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
cephalosporinA class of beta-lactam antibiotics differing from the penicillins in having a 6-membered, rather than a 5-membered, side ring. Although cephalosporins are among the most commonly used antibiotics in the treatment of routine infections, and their use is increasing over time, they can cause a range of hypersensitivity reactions, from mild, delayed-onset cutaneous reactions to life-threatening anaphylaxis in patients with immunoglobulin E (IgE)-mediated allergy.
carboxylic acidA carbon oxoacid acid carrying at least one -C(=O)OH group and having the structure RC(=O)OH, where R is any any monovalent functional group. Carboxylic acids are the most common type of organic acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
estrogen nuclear receptor alphaHomo sapiens (human)Potency23.80060.000229.305416,493.5996AID743075; AID743079
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency39.81070.354828.065989.1251AID504847
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (56)

Assay IDTitleYearJournalArticle
AID540221Volume of distribution at steady state in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1171222Ratio of MIC for wild-type tolC-deficient Escherichia coli in presence of 2% HSA to MIC for tolC-deficient Escherichia coli in presence of 2% HSA2014Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23
Trends and exceptions of physical properties on antibacterial activity for Gram-positive and Gram-negative pathogens.
AID1211546Biliary excretion in Eisai hyperbilirubinemic mutant rat at 20 mg/kg, iv administered as single dose by HPLC analysis2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
AID1211872Total biliary clearance in Sprague-Dawley rat at 20 mg/kg, iv2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID1211887Unbound biliary clearance in beagle dog at 20 mg/kg, iv2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1211809Drug excretion in beagle dog assessed as compound excreted into bile at 20 mg/kg, iv2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID1171215Antibacterial activity against wild-type Escherichia coli2014Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23
Trends and exceptions of physical properties on antibacterial activity for Gram-positive and Gram-negative pathogens.
AID1211804Drug excretion in Sprague-Dawley rat assessed as compound excreted into bile at 20 mg/kg, iv2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID1211556Total clearance in Eisai hyperbilirubinemic mutant rat at 20 mg/kg, iv administered as single dose by HPLC analysis2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
AID1211555In vitro apparent biliary clearance in sandwich cultured Sprague-Dawley rat hepatocytes after 15 mins by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1171220Antibacterial activity against wild-type Staphylococcus aureus in presence of 2% HSA2014Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23
Trends and exceptions of physical properties on antibacterial activity for Gram-positive and Gram-negative pathogens.
AID1211880Unbound biliary clearance in Sprague-Dawley rat at 20 mg/kg, iv2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1211553Drug uptake in iv dosed Sprague-Dawley rat liver after 5 hrs by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID540215Volume of distribution at steady state in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID540217Volume of distribution at steady state in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1211551Drug uptake in sandwich cultured Sprague-Dawley rat hepatocytes by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
AID1211552In vitro intrinsic biliary clearance in sandwich cultured Sprague-Dawley rat hepatocytes by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
AID1211856Unbound biliary clearance in human at 1 gm, iv after 24 hrs by T-tube method2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1211836Total biliary clearance in human at 1 gm, iv after 24 hrs by T-tube method2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1171214Antibacterial activity against tolC-deficient Escherichia coli in presence of 2% HSA2014Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23
Trends and exceptions of physical properties on antibacterial activity for Gram-positive and Gram-negative pathogens.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1211817Drug excretion in human assessed as compound excreted into bile at 1 gm, iv after 24 hrs by T-tube method2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID1211549Unbound fraction in Sprague-Dawley rat plasma at 100 uM by equilibrium dialysis method2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID540218Clearance in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID540214Clearance in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1171219Antibacterial activity against wild-type Staphylococcus aureus2014Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23
Trends and exceptions of physical properties on antibacterial activity for Gram-positive and Gram-negative pathogens.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID540220Clearance in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID540219Volume of distribution at steady state in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1211550In vivo intrinsic biliary clearance in iv dosed Sprague-Dawley rat by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1211548In vivo apparent biliary clearance in iv dosed Sprague-Dawley rat by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
AID540216Clearance in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1171213Antibacterial activity against tolC-deficient Escherichia coli2014Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23
Trends and exceptions of physical properties on antibacterial activity for Gram-positive and Gram-negative pathogens.
AID1211554Biliary excretion index in sandwich cultured Sprague-Dawley rat hepatocytes after 15 mins by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
AID1211885Total biliary clearance in beagle dog at 20 mg/kg, iv2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (125)

TimeframeStudies, This Drug (%)All Drugs %
pre-199088 (70.40)18.7374
1990's22 (17.60)18.2507
2000's5 (4.00)29.6817
2010's8 (6.40)24.3611
2020's2 (1.60)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.21

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.21 (24.57)
Research Supply Index4.91 (2.92)
Research Growth Index4.44 (4.65)
Search Engine Demand Index39.34 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (29.21)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials8 (6.35%)5.53%
Reviews1 (0.79%)6.00%
Case Studies10 (7.94%)4.05%
Observational0 (0.00%)0.25%
Other107 (84.92%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]